HeartBeam
HeartBeam is a publicly traded cardiac technology company (NASDAQ: BEAT) that has developed a first-of-its-kind, credit card-sized, cable-free device (HeartBeam AIMIGo) capturing 3D ECG signals and synthesizing a 12-lead ECG for at-home arrhythmia assessment, targeting preventive cardiology, concierge medicine, and—via a June 2026 pivot—licensing to OEMs, health systems, and wearable device makers.
- Company typePublic
- Founded2015
- HeadquartersSanta Clara, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What HeartBeam does
HeartBeam, Inc. is a publicly traded cardiac medical technology company (NASDAQ: BEAT) that has developed a 3D-vector electrocardiogram (VECG) platform consisting of a credit card-sized, cable-free device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix. The core FDA-cleared HeartBeam System and 12-Lead ECG Synthesis Software (cleared December 2025) are paired with a patient-facing mobile app, cloud infrastructure, and clinician portal for on-call physician review. The technology is protected by over 20 issued patents worldwide, was originated by Founder Branislav Vajdic, and is being extended through pipeline products including an on-demand 12-lead ECG patch, the HeartBeam AI deep-learning suite for arrhythmia and heart attack detection, and the acquired LIVMOR Halo+ Atrial Fibrillation Detection System.
The company operates in the cardiac diagnostics space with a primary focus on enabling clinical-grade 12-lead ECG capture outside traditional healthcare facilities. HeartBeam initially pursued direct sales into the high-value direct-pay and preventive cardiology segment through concierge and preventive cardiology practices such as ClearCardio (first commercial customer, March 2026) and Atelier Health (May 2026, covering four U.S. launch markets: New York metro, Dallas, South Florida, Southern California). In June 2026, the company announced a strategic reorganization under Founder/President Branislav Vajdic and Executive Chairman Rich Ferrari to shift from direct medical device sales to licensing its patented 3D ECG platform to established partners — governments, health systems, ECG manufacturers, and wearable device companies — across five distribution channels to accelerate global adoption.
HeartBeam's commercial economics are pre-revenue: Q1 2026 reported no recognized revenue and FY2025 showed a $21.0 million net loss. The company has funded operations through post-IPO public offerings totaling roughly $45 million since 2023 and filed a $100 million shelf registration in March 2026, with insider ownership around 18% and a market capitalization of approximately $47.25 million as of April 2026. Strategic collaborations with Mount Sinai (AI-ECG algorithm development) and AccurKardia (ECG analysis software integration) are intended to deepen the platform's clinical and AI capabilities and support combined FDA clearance paths.
HeartBeam firmographics
Firmographics- Name
- HeartBeam
- Legal name
- HeartBeam, Inc.
- Website
- https://heartbeam.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HeartBeam is a publicly traded cardiac technology company (NASDAQ: BEAT) that has developed a first-of-its-kind, credit card-sized, cable-free device (HeartBeam AIMIGo) capturing 3D ECG signals and synthesizing a 12-lead ECG for at-home arrhythmia assessment, targeting preventive cardiology, concierge medicine, and—via a June 2026 pivot—licensing to OEMs, health systems, and wearable device makers.
- Ownership category
- akta.pro rank
HeartBeam industry classification
Industry- Product category
- Cardiac Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
Keywords
Where HeartBeam is headquartered
LocationHeadquarters
- HQ city
- Santa Clara
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
HeartBeam business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Hardware sales (commercial launch): HeartBeam began commercial-stage operations in early 2026 with FDA clearance of its synthesized 12-lead ECG system. Q1 2026 reported no revenue recognized, indicating commercial sales were still in early-stage ramp-up following ClearCardio as first commercial customer.
- Licensing of 3D ECG signal technology platform: Following strategic reorganization in June 2026, HeartBeam is shifting from direct medical device sales to licensing its patented 3D ECG signal technology platform to established partners (governments, health systems, ECG manufacturers, wearable device companies) across five distribution channels to accelerate global adoption and reduce costs.
- Strategic collaboration / co-development revenue: Collaboration with AccurKardia to integrate FDA-cleared ECG analysis software into HeartBeam's device for automated rhythm assessment, with plans for combined FDA clearance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Commercial launch with Letter of Intent structure; quote-based pricing not publicly disclosed |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
HeartBeam product offering
Product offeringCore offering
HeartBeam develops a cable-free, credit-card-sized ECG device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix, paired with a cloud platform, patient-facing mobile app, and clinician portal for at-home arrhythmia assessment. The FDA-cleared core platform is being expanded into heart attack (ischemia) detection and licensed to OEMs/wearable device makers under a 2026 strategic shift.
Product overview
HeartBeam offers an integrated cardiac care platform built around a single FDA-cleared core hardware device (the HeartBeam System) paired with its companion 12-Lead ECG Synthesis Software, delivered primarily through the credit card-sized portable HeartBeam AIMIGo device. The system architecture combines the hardware recorder (capturing 3-Lead ECG from three directions via 5 electrodes), cloud synthesis (personalized transformation matrix producing a synthesized 12-Lead ECG), the patient-facing mobile app, and the clinician portal for manual interpretation. Acquired assets (the LIVMOR Halo+ Atrial Fibrillation Detection System) extend remote monitoring reach. Pipeline offerings include the investigational extended-wear 12-Lead ECG Patch, the HeartBeam AI deep-learning capabilities (atrial fibrillation/flutter detection), and the Ischemia Detection Product targeting heart attack assessment.
Differentiator
Problem solved
Functional benefit
Brands
- HeartBeam AIMIGo: Credit card-sized, cable-free device that captures heart signals in three dimensions and synthesizes a 12-lead ECG for at-home arrhythmia assessment.
- HeartBeam AIMI
- HeartBeam System
- HeartBeam 12-Lead ECG Synthesis Software
Products and services
- HeartBeam AIMIGo A credit card-sized, portable, cable-free device that captures the heart's electrical signals from three dimensions and synthesizes a 12-lead ECG using a personalized transformation matrix. The patient places the device on the chest for a 30-second recording that is sent to the cloud for on-call cardiologist review.
- HeartBeam 12-Lead ECG Synthesis Software Software that synthesizes a 12-Lead ECG from the HeartBeam System's 3-Lead (in three-directions) recording using a personalized transformation matrix, producing a visual 12-Lead ECG for manual assessment of non-life-threatening arrhythmias by a physician or healthcare professional.
- HeartBeam System (3-Lead ECG Recorder) A portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) ECG acquired from 5 electrodes, used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation.
- Halo+ Atrial Fibrillation Detection System An FDA-cleared remote monitoring system for physiological markers with atrial fibrillation detection capability, acquired from LIVMOR along with related patents, technology, business contracts, and inventory.
- HeartBeam AIMI Software designed for acute care settings that compares ECGs to identify heart attacks. Patented product in regulatory resubmission for remote cardiac evaluation in acute care environments.
Quantifiable outcome
- 86.5% AUC for heart attack detection with a single reading; 92.9% AUC when baseline ECG was available (184-patient study published in JACC: Advances)
- +4 more outcomes
Companies that use HeartBeam
Customer profileNamed customers4 records
Segments6 records
Ideal customer profiles5 records
HeartBeam technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature8 records
HeartBeam partnerships and signals
Strategic signalPartnerships
Five partnerships are on record.
- Atelier HealthCommercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center, to offer HeartBeam's cable-free 3D ECG technology to patients. Expands commercial footprint across four targeted U.S. launch markets: New York metro, Dallas, South Florida, and Southern California, completing initial geographic foundation for scalable growth.
- VentriPoint Diagnostics / First Light HealthMentioned in coverage of decentralized AI in cardiac diagnostics: VentriPoint Diagnostics partnered with First Light Health to deploy AI-powered cardiac diagnostics using VentriPoint's VMS+ system in remote and Indigenous communities across Canada. HeartBeam mentioned alongside as developing AI-enabled cardiac diagnostics. (Indirect context; HeartBeam parallel developments referenced.)
- Mount SinaiStrategic AI collaboration to develop advanced AI-ECG algorithms, integrating Mount Sinai's clinical expertise with HeartBeam's 3D ECG technology. The partnership aims to develop a new platform capable of collecting 12-lead ECG data from patients at home, enabling scalable, personalized cardiac health assessments in real-world settings and supporting broader applications in preventive cardiology and chronic disease management.
- AccurKardiaStrategic collaboration to develop cardiac monitoring solutions by integrating AccurKardia's FDA-cleared ECG analysis software into HeartBeam's device for automated rhythm assessment and expedited cardiac diagnosis. Plans include joint FDA clearance efforts. Earlier reported on prlog (2026-04-21) as forming a collaboration to enhance cardiac monitoring through ambulatory ECG recording and analysis.
- LIVMOR, Inc.HeartBeam acquired substantially all assets of LIVMOR, including the FDA-cleared Halo+ Atrial Fibrillation Detection System, related technology, patents, business contracts, inventory, and key technical staff. The acquisition built on a 2022 partnership between HeartBeam and LIVMOR to develop HeartBeam-branded versions of LIVMOR's cardio health software platform.
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
HeartBeam competitors and assessment
Company assessmentDirect peers
- iRhythm Technologies: iRhythm's Zio long-term continuous ambulatory ECG monitor competes in the same remote cardiac monitoring category as HeartBeam's investigational extended-wear patch and arrhythmia assessment platform.
- AliveCor: AliveCor makes KardiaMobile, a consumer/clinical single-lead ECG device paired with AI-based arrhythmia detection. Directly comparable as a portable, patient-facing ECG platform targeting arrhythmia assessment outside the clinic, and a former employer of HeartBeam's CCO.
- Eko Health: Eko Health builds digital stethoscopes with embedded ECG and AI algorithms for cardiac and pulmonary assessment. Comparable as a portable AI-ECG platform aimed at clinicians and remote monitoring, and also a former employer of HeartBeam's CCO.
Broad incumbents
- Preventice Solutions (Boston Scientific): Now part of Boston Scientific, Preventice offers BodyGuardian remote cardiac monitoring (patch and event monitor) for ambulatory arrhythmia detection — directly comparable in use case and overlaps with HeartBeam's extended-wear patch and ambulatory ECG ambitions.
- Apple (Apple Watch ECG): Apple Watch offers FDA-cleared single-lead ECG and AFib detection features to a massive consumer installed base. While limited to single-lead and consumer use, it sets expectations for at-home ECG and is a frequent reference point in HeartBeam's competitive positioning.
- GE HealthCare: GE HealthCare manufactures resting ECG, stress, and Holter monitoring systems used in hospitals and clinics. Comparable as a broad incumbent ECG vendor and a potential licensing/OEM partner for HeartBeam's 3D ECG signal platform.
- Philips (Cardiac Monitoring): Philips provides a broad portfolio of resting ECG, Holter, and remote cardiac monitoring solutions (including the recently divested BioTelemetry assets). Comparable as an established multi-channel ECG and cardiac monitoring vendor that HeartBeam could partner with or compete against under the licensing model.
Emerging players
- HeartFlow: HeartFlow offers AI-driven non-invasive cardiac diagnostics (FFR-CT for coronary disease). Comparable as a technology-enabled cardiac diagnostics company focused on actionable clinical insights, and a former employer of HeartBeam's CCO.
- Cardiac Insight: Cardiac Insight provides the Cardea SOLO wearable ECG sensor and automated arrhythmia analysis software for ambulatory cardiac screening. Comparable as a smaller, ambulatory, AI-ECG player in the same patient-monitoring category as HeartBeam.
- AccurKardia: AccurKardia develops FDA-cleared ECG analysis software for automated rhythm assessment. Already a strategic partner of HeartBeam for integrated rhythm analysis, and closely comparable as an AI-ECG software platform with overlapping arrhythmia detection IP.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
HeartBeam social profiles
Digital presenceHeartBeam compliance and trust
Trust signalCompliance1 record
HeartBeam financial estimates
Financial estimateRevenue estimate
Valuation estimate
HeartBeam leadership team
Management profileNumber of profiles
Profiles8 records
HeartBeam subsidiaries and ownership
Company hierarchySubsidiaries1 record
HeartBeam funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HeartBeam M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HeartBeam
What does HeartBeam do?
HeartBeam develops a cable-free, credit-card-sized ECG device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix, paired with a cloud platform, patient-facing mobile app, and clinician portal for at-home arrhythmia assessment. The FDA-cleared core platform is being expanded into heart attack (ischemia) detection and licensed to OEMs/wearable device makers under a 2026 strategic shift.
Is HeartBeam a public or private company?
HeartBeam is a public company. It is classified as public and is currently operating.
When was HeartBeam founded?
HeartBeam was founded in 2015. It employs 11 to 50 people.
Where is HeartBeam based?
HeartBeam is headquartered in Santa Clara, United States, in the North America region.
How does HeartBeam make money?
Three revenue lines are on record. Hardware sales (commercial launch) is the primary driver. The others are licensing of 3D ECG signal technology platform and strategic collaboration / co-development revenue.
Who are HeartBeam's main competitors?
Direct peers on record are iRhythm Technologies, AliveCor and Eko Health. Broad incumbents are Preventice Solutions (Boston Scientific), Apple (Apple Watch ECG), GE HealthCare and Philips (Cardiac Monitoring). Emerging players are HeartFlow, Cardiac Insight and AccurKardia.
Does HeartBeam have an API?
No public API is recorded for HeartBeam.
What industry is HeartBeam in?
HeartBeam's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3845.